anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The method for the complex treatment of schizophrenia with the continuous course and suicidal behavior comprises the use of Rispolept with accompanying central electroanalgesia. The daily oral dose of Rispolept increases within the week up to the average dose 5 mg daily. The electroanalgesia is performed in 1.5 hours after the morning dose of Rispolept is taken. The alternate mode of relative pulse duration is followed. In the course of the treatment, the current is augmented from 0.8 to 1.2 mA, the pulse frequency û from 200 to 1000 Hz, the pulse duration û from 1.2 to 1.3 ms, the duration of the procedure û from 45 to 50 min. The overall course of the treatment comprises 10 daily sessions.
This study leverages the most up-to-date lipidomic data to provide fresh perspectives on the treatment and prevention of atopic dermatitis. The analysis utilized genome-wide association study (GWAS) data on 179 circulating plasma lipids and AD GWAS data. The primary analysis method employed was the inverse variance weighting (IVW) method, and several sensitivity analyses were conducted to ensure the reliability of the results. Additionally, summary-data-based MR (SMR) and colocalization analysis were utilized to investigate the underlying biological pathways of AD. After rigorous analyses, the IVW method utilized in TSMR analysis pinpointed six plasma lipids with potentially reduced AD risk when elevated. Subsequently, MVMR analysis revealed that there is no independent causal effect of different lipids within the same subtype on AD. Bidirectional MR analysis did not indicate reverse causality, and SMR analysis suggested FADS1 and FADS2 as potential drug targets for AD treatment. This MR study demonstrated a causal relationship between specific plasma lipid levels and AD risk at the genetic level, which can be used for clinical screening of AD plasma lipid biomarkers and provides a novel perspective on potential therapeutic strategies.
The invention relates to a novel anti-tumor small molecular leading compound of a targeting tumor related protein which is synthesized based on a virtual screening platform of drugs. The virtual screening platform of drugs is combined with bioinformatics and computer technology. The small molecular leading compound has the advantages of good penetrability, small toxic and side effect, simple structure and easy to synthesize and etc.; moreover, the small molecular leading compound can be combined with Tumor Necrosis Factor (TNF-alpha) to strengthen the tumor-killing effect of the TNF-alpha, thus playing the role of treating tumors. Therefore, the small molecular leading compound is expected to be developed into a novel anti-tumor drug. The small molecular leading compound also relates to a medicinal composition containing the small molecular leading compound and purposes thereof.
Five physiotherapists (GP) with at least 5 years of experience in the technique were selected to perform the technique on the simulator and complete a questionnaire in order to evaluate the texture and skin elasticity, the curvature and size of the cervical spine format. They scored these items from the Likert scale. After evaluation they used the simulator to generate a standard guide training.
BACKGROUND: Acute pancreatitis (AP) is a prevalent exocrine inflammatory disorder of the pancreas characterized by pancreatic inflammation and injury to acinar cells. Vitamin B6 (VB6) is a vital nutrient that plays a significant role in preserving human health and has anti-inflammatory and anti-apoptotic effects.
METHODS: This study aimed to explore the potential pancreatic protective effects of VB6 in mitigating pancreatic inflammation and apoptosis induced by taurocholate sodium (TLCS) in an AP model and to assess the underlying mechanism of action. AP was induced in Sprague‒Dawley (SD) rats through TLCS administration and lipopolysaccharide (LPS)-treated AR42J cells, followed by treatment with VB6.
RESULTS: Various parameters associated with AP were assessed in both plasma and pancreatic tissues. VB6 has been shown to ameliorate the severity of AP through various mechanisms. It effectively reduces the levels of serum amylase, lipase, and inflammatory factors, thereby mitigating histological injury to the pancreas. Moreover, VB6 inhibited pancreatic apoptosis by downregulating bax expression and up-regulating Bcl2 expression in TLCS-treated rats. Additionally, VB6 suppressed the expression of caspase3. The anti-inflammatory and anti-apoptotic effects of VB6 observed in LPS-treated AR42J cells are consistent with those observed in a rat model of AP.
CONCLUSIONS: These results suggest that VB6 exerts anti-inflammatory and anti-apoptotic effects through inhibition of the caspase3 signaling pathway and has a protective effect against AP.
Phase II arm 1b will randomize 30 patients to LGX818. Single agent anti-tumor activity of LGX818 is comparable to other BRAFi that are either approved or in clinical trials. This single agent anti-tumor activity will be compared to that of the combination (LEE011 + LGX818) in the BRAFi naïve patient population.
PURPOSE:To enable the simple and effective application of a drug for transcutaneous absorption to the skin, by coating the skin with a solution of a polymer containing the transcutaneous absorption drug, and sealing the coated skin with the coating film of a stretchable and drug-impermeable polymer. CONSTITUTION:A polymer containing a drug for transcutaneous absorption (e.g. corticosteroid, anesthetic, analgesic and anti-inflammatory agent, etc.) or a mixture of said drug and an agent for promoting the transcutaneous absorption, is applied to the skin. The coated skin is further coated with a solution of a film- forming polymer impermeable to the drug or the agent and having an elongation of >=20%, in a manner to seal the applied drug. The drug-containing polymer is e.g. rubber, polyurethane, etc., and the film-forming polymer is preferably poly (meth)acrylate polymer. The loss of the drug can be reduced, the polymer film has excellent adhesivity to the skin and does not hinder the bending of the applied part, and a sufficiently high drug activity can be attained.
Thealoz® Duo, (trehalose 3%/sodium hyaluronate 0.15%). Ophthalmic Solution. One drop QID, both eyes (OU) for 14 days.
A method for modeling a dental arch of a patient. Creation of a historical library including more than 1000 historical tooth models, and assignment, to each historical tooth model, of a value for at least one tooth attribute value. Analysis of at least one analysis image of the dental arch by means of a deep learning device so as to determine at least one analysis tooth zone and at least one tooth attribute value. For each analysis tooth zone determined in the preceding step, search, in the historical library, for a historical tooth model exhibiting a maximal proximity with the analysis image. Arrangement of all of the optimal tooth models so as to create an assembled model which exhibits a maximal proximity. Some optionally steps are possible.
Tumours can obtain nutrients and oxygen required to progress and metastasize through the blood supply1. Inducing angiogenesis involves the sprouting of established vessel beds and their maturation into an organized network2,3. Here we generate a comprehensive atlas of tumour vasculature at single-cell resolution, encompassing approximately 200,000 cells from 372 donors representing 31 cancer types. Trajectory inference suggested that tumour angiogenesis was initiated from venous endothelial cells and extended towards arterial endothelial cells. As neovascularization elongates (through angiogenic stages SI, SII and SIII), APLN+ tip cells at the SI stage (APLN+ TipSI) advanced to TipSIII cells with increased Notch signalling. Meanwhile, stalk cells, following tip cells, transitioned from high chemokine expression to elevated TEK (also known as Tie2) expression. Moreover, APLN+ TipSI cells not only were associated with disease progression and poor prognosis but also hold promise for predicting response to anti-VEGF therapy. Lymphatic endothelial cells demonstrated two distinct differentiation lineages: one responsible for lymphangiogenesis and the other involved in antigen presentation. In pericytes, endoplasmic reticulum stress was associated with the proangiogenic BASP1+ matrix-producing pericytes. Furthermore, intercellular communication analysis showed that neovascular endothelial cells could shape an immunosuppressive microenvironment conducive to angiogenesis. This study depicts the complexity of tumour vasculature and has potential clinical significance for anti-angiogenic therapy.
A modified polyalkylene oxide which is obtained by reacting a polyalkylene oxide compound (A), a polyether monoalcohol (B) and a diisocyanate compound (C). The compound (A) is a polyethylene oxide represented by formula (II). HO-(CH2CH2O)n-H (II) (In formula (II), n represents an integer of 130-680.) The compound (B) is a polyether monoalcohol which has a structure wherein one end of a random copolymer of ethylene oxide and propylene oxide is an OH group and the other end is a linear alkyl group having 15-24 carbon atoms, and wherein if a is the mole number of added ethylene oxide and b is the mole number of added propylene oxide, (a/b) is 1-2. The compound (C) is at least one diisocyanate compound that is selected from the group consisting of compounds represented by formula (IV). O=C=N-R2-N=C=O (IV) (In formula (IV), R2 represents a methyl diphenylene group, a hexamethylene group, a methyl dicyclohexylene group, a 3-methyl-3, 5, 5-trimethyl cyclohexylene group, a dimethyl phenylene group or a tolylene group.)
PURPOSE: To obtain an oil-in-water type cream base material having excellent functional feeling and stability and effective for protection of ultraviolet rays by containing a colloidal water-containing silicate, a polyethylene glycol and fine particle powder and emulsifying by a microfluidizer. CONSTITUTION: This base material contains 0.2-10wt.% of a colloidal water- containing silicate, 0.2-10wt.% of a polyethylene glycol having 1000-10000 average molecular weight and 0.01-30wt.% fine particle powder (e.g. titanium oxide). Further, preferably 0.01-5wt.% crystalline cellulose, an ultraviolet ray absorber (e.g. ethyl para-aminobenzoate) and a water-soluble polymer (e.g. hyaluronic acid) are mixed. The above components are blended, and emulsified by a microfluidizer and the powder is uniformly dispersed to obtain the objective base material having sustaining effect without self-emulsifying by sweat, etc., because of not containing a surfactant. When an ultraviolet ray absorber is combinedly used, penetration of ultraviolet rays into the skin is prevented, and safety is high because a surfactant is not mixed.
Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics. Doses as low as 5 mg cause substantial blockage of LTD 4-induced bronchoconstriction. In a placebo-controlled, crossover study (n=12), montelukast sodium inhibited early- and late-phase bronchoconstriction due to antigen challenge by 75% and 57%, respectively.

The effect of montelukast sodium on eosinophils in the peripheral blood was examined in clinical trials. In patients with asthma aged 2 years and older who received montelukast sodium, a decrease in mean peripheral blood eosinophil counts ranging from 9% to 15% was noted, compared with placebo, over the double-blind treatment periods. In patients with seasonal allergic rhinitis aged 15 years and older who received montelukast sodium, a mean increase of 0.2% in peripheral blood eosinophil counts was noted, compared with a mean increase of 12.5% in placebo-treated patients, over the double-blind treatment periods; this reflects a mean difference of 12.3% in favor of montelukast sodium. The relationship between these observations and the clinical benefits of montelukast noted in the clinical trials is not known [see Clinical Studies (14)].
It will include subjects with Refractory Diffuse Large B-cell Lymphoma and Multiple Myeloma, Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) and/or who participated in a CAR-T clinical trial or autologous treatment. Subjects will undergo a telephonic interview for up to 90 minutes.
PURPOSE:An antitumor agent having high antitumor action, alleviating or preventing side effects, obtained by blending an interleukin 2 activator with a specific glucan as active ingredients. CONSTITUTION:An antitumor agent containing a blend obtained by combining interleukin 2(IL-2 for short) with a straight-chain beta-1,3-glucan (e.g. sizofilan) which may contain glucose residue by beta-1,6-bond as a side chain, a partial hydrolyzate or a carboxymethylated substance thereof. Both IL-2 and the gluan have been used as an antitumor substance, a method of increasing dose is applied to raise antitumor effects, but manifestation of side effects such as pyrexia, headache, rash, etc., is sometimes found. Use of both the substances raises antitumor effects and alleviates side effects. In the antitumor substance, both the substances are blended and applied as one drug or may be separately or simultaneously administered or in a time lag.
Use with caution in severe renal disease. In patients with renal disease, thiazides may precipitate azotemia. Cumulative effects of the drug may develop in patients with impaired renal function.

Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.

Thiazides may add to or potentiate the action of other antihypertensive drugs.

Sensitivity reactions may occur in patients with or without a history of allergy or bronchial asthma.

The possibility of exacerbation or activation of systemic lupus erythematosus has been reported.

Lithium generally should not be given with diuretics (see PRECAUTIONS: Drug Interactions). 

Acute Myopia and Secondary Angle-Closure Glaucoma:Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
Carboplatin AUC = 2, Paclitaxel 50 mg/m2 (both weekly) , a total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy. Panitumumab panitumumab: 6mg/kg in weeks 1-3-5.
Amlodipine besylate, USP, is the besylate salt of amlodipine, a long-acting calcium channel blocker.

Amlodipine besylate is chemically described as 3-Ethyl-5-methyl (±)-2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate, monobenzenesulphonate. Its molecular formula is C20H25ClN2O5•C6H6O3S, and its structural formula is:

Amlodipine besylate is a white crystalline powder with a molecular weight of 567.1. It is slightly soluble in water and sparingly soluble in ethanol. Amlodipine Besylate Tablets are formulated as white tablets equivalent to 5 and 10 mg of amlodipine for oral administration. In addition to the active ingredient, amlodipine besylate, each tablet contains the following inactive ingredients: microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate, and magnesium stearate.
The safety and efficacy of BARACLUDE were assessed in a single-arm, open-label trial in 65 subjects who received a liver transplant for complications of chronic HBV infection. Eligible subjects who had HBV DNA less than 172 IU/mL (approximately 1000 copies/mL) at the time of transplant were treated with BARACLUDE 1 mg once daily in addition to usual post-transplantation management, including hepatitis B immune globulin. The trial population was 82% male, 39% Caucasian, and 37% Asian, with a mean age of 49 years; 89% of subjects had HBeAg-negative disease at the time of transplant.

Four of the 65 subjects received 4 weeks or less of BARACLUDE (2 deaths, 1 re-transplantation, and 1 protocol violation) and were not considered evaluable. Of the 61 subjects who received more than 4 weeks of BARACLUDE, 60 received hepatitis B immune globulin post-transplant. Fifty-three subjects (82% of all 65 subjects treated) completed the trial and had HBV DNA measurements at or after 72 weeks treatment post-transplant. All 53 subjects had HBV DNA <50 IU/mL (approximately 300 copies/mL). Eight evaluable subjects did not have HBV DNA data available at 72 weeks, including 3 subjects who died prior to study completion. No subjects had HBV DNA values ≥50 IU/mL while receiving BARACLUDE (plus hepatitis B immune globulin). All 61 evaluable subjects lost HBsAg post-transplant; 2 of these subjects experienced recurrence of measurable HBsAg without recurrence of HBV viremia. This trial was not designed to determine whether addition of BARACLUDE to hepatitis B immune globulin decreased the proportion of subjects with measurable HBV DNA post-transplant compared to hepatitis B immune globulin alone.

If BARACLUDE treatment is determined to be necessary for a liver transplant recipient who has received or is receiving an immunosuppressant that may affect renal function, such as cyclosporine or tacrolimus, renal function must be carefully monitored both before and during treatment with BARACLUDE [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].
OBJECTIVE: To explore how Qingfei Zhisou oral liquid (, QFZS) adjusts body temperature bias and the interaction of inflammatory factors levels and metabolomic differences.
METHODS: Dry yeast was subcutaneously injected at 10 mL/kg to establish the pyrexia model. We randomly divided 60 Sprague-Dawley rats into five groups: control, model, positive, low dose of QFZS and high dose of QFZS. Inflammatory proteins were evaluated by Western blotting and immunohistochemistry. For the examination of the endogenous metabolites, enzyme linked immunosorbent assay and ultra-high-performance liquid chromatography high-resolution mass spectrometry were employed.
RESULTS: QFZS significantly reduced rats' body temperature within 6 h after dry yeast injection and reduced the secretion of the arginine vasopressin, cyclic adenosine monophosphate, prostaglandin E-2, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β in serum. Meanwhile, we identified 41 metabolites between the model and QFZS groups, including arachidonic acid and lysophospholipids. QFZS restored normal arachidonic acid levels. Based on the differential metabolite enrichment analysis, QFZS's anti-inflammatory and anti-pyrexia effects might be related to the inflammatory pathway regulated by transient receptor potential. Additionally, QFZS treatment reduced transient receptor potential melastatin 2 ion channel expression and affected TNF-α, heat shock protein 70, and cyclooxygenase-2 expression in the hypothalamus.
CONCLUSION: QFZS exerts its regulatory effects on fever by regulating the metabolism of lysophospholipids and arachidonic acid and the regulation of inflammation via transient receptor potential ion channels channels.
It is well established that humoral immunity targeting hepatitis B virus surface antigen (HBsAg) plays a critical role in viral clearance and clinical cure. However, the functional changes in HBsAg-specific B cells before and after achieving functional cure remain poorly understood. In this study, we characterized circulating HBsAg-specific B cells and identified functional shifts and B-cell epitopes directly associated with HBsAg loss. The phenotypes and functions of HBV-specific B cells in patients with chronic HBV infection were investigated using a dual staining method and the ELISpot assay. Epitope mapping was performed to identify B cell epitopes associated with functional cure. Hyperactivated HBsAg-specific B cells in patients who achieved HBsAg loss were composed of enriched resting memory and contracted atypical memory fractions, accompanied by sustained co-expression of multiple inhibitory receptors and increased IL-6 secretion. The frequency of HBsAb-secreting B cells was significantly increased after achieving a functional cure. The rHBsAg displayed a weaker immunomodulatory effect on B cells than rHBeAg and rHBcAg in vitro. Notably, sera from patients with HBsAg loss reacted mainly with peptides S60, S61, and S76, suggesting that these are dominant linear B-cell epitopes relevant for functional cure. Intriguingly, patients reactive with S76 showed a higher frequency of the HLA class II DQB1*05:01 allele. Taken together, HBsAg-specific B cells were partially restored in patients after achieving a functional cure. Functional cure-related epitopes may be promising targets for developing therapeutic vaccines to treat HBV infection and promote functional cure.
Acute hyperglycemia is a common endocrine and metabolic disorder that seriously threatens the health and life of patients. Exploring effective diagnostic methods and treatment strategies for acute hyperglycemia to improve treatment quality and patient satisfaction is currently one of the hotspots and difficulties in medical research. This article introduced a method for diagnosing acute hyperglycemia based on data-driven prediction models. In the experiment, clinical data from 1000 patients with acute hyperglycemia were collected. Through data cleaning and feature engineering, 10 features related to acute hyperglycemia were selected, including BMI (Body Mass Index), TG (triacylglycerol), HDL-C (High-density lipoprotein cholesterol), etc. The support vector machine (SVM) model was used for training and testing. The experimental results showed that the SVM model can effectively predict the occurrence of acute hyperglycemia, with an average accuracy of 96 %, a recall rate of 84 %, and an F1 value of 89 %. The diagnostic method for acute hyperglycemia based on data-driven prediction models has a certain reference value, which can be used as a clinical auxiliary diagnostic tool to improve the early diagnosis and treatment success rate of acute hyperglycemia patients.
TRAMPRE is an acronym that defines multimodal interventions discharge training. TRAMPRE will be applied to the participants in line with the "Preterm Baby Care Guide" at the discharge stage. Weekly telephone follow-up will be carried out for 12 weeks after discharge. Applications to be made to the initiative group are given below. Phone Follow-up/Interview: During the first 12 weeks following the discharge of the preterm baby, parents will be interviewed by phone at least once a week.